Polymorphisms in Tumour Necrosis Factor Alpha (TNFα) Gene in Patients with Acute Pancreatitis

Proinflammatory cytokines, such as tumour necrosis factor α (TNFα), play fundamental roles in the pathogenesis of acute pancreatitis (AP). The aim of this study was to determine if polymorphisms in the TNFα gene are associated with AP. Two polymorphisms located in the promoter region (positions −308 and −238) in TNFα gene were determined using polymerase chain reaction- (PCR-) restriction fragment length polymorphism (RFLP) methods in 103 patients with AP and 92 healthy controls. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated using logistic regression analysis adjusted for age, sex, BMI and smoking. The frequencies of TNFα polymorphisms were both similar in patients with mild or severe pancreatitis, so were in pancreatitis patients and in controls. We suggest that both SNPs of TNFα are not genetic risk factor for AP susceptibility (OR = 1.63; 95% CI: 1.13−4.01 for TNFα−308 and OR = 0.86; 95% CI: 0.75−1.77 for TNFα−238)

Acute myocarditis mimicking acute myocardial infarction associated with pandemic 2009 (H1N1) influenza A virus

The prevalence of myocardial involvement in influenza infection ranges from 0% to 11% depending on the diagnostic criteria used to define myocarditis. Whether such an association holds for the novel influenza A strain, pandemic-2009-H1N1, remains unknown. The clinical presentation of myocarditis varies and often mimics myocardial infarction. Although history, physical examination, laboratory data points, and electrocardiogram are helpful in distinguishing myocarditis from myocardial infarction, differential diagnosis can sometimes be difficult. Here, we present the first known report of acute myocarditis mimicking acute myocardial infarction associated with the pandemic influenza A virus (H1N1) infection. (Cardiol J 2011; 18, 5: 552–555

Yttrium-90 radioembolization for the treatment of unresectable liver cancer: Results of a single center

Objective: To determine the effects of yttrium-90 (Y-90) resin microsphere radioembolization therapy on patients with unresectable liver cancer who do not benefit from chemotherapy. Methods: Fifty-five patients underwent radioembolization therapy included in the study whose had unresectable primary or metastatic liver cancer originating from the gastrointestinal tract. Three were excluded from the study after pre-evaluation angiography. Thirteen (23.6%) of the remaining 52 patients had hepatocellular carcinoma and 39 (76.4%) had metastatic liver cancer. Fifty-two patients underwent Y-90 radioembolization treatment. Each patient's response to the administered treatment was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) and the overall probability of survival was displayed graphically by the Kaplan-Meier method. Results: After Y-90 therapy, 47 patients were follow-up. While 57% of the patients responded to treatment as clinical benefit, the disease progressed in 43%. The median hepatic progression-free survival time of the patients was 3.4 months (95% confidence interval (ci):1.4-5.3) and the overall survival time was 11.3 months (95%, CI:8.7-14.03). Conclusion: This study emphasizes that Y-90 resin microsphere radioembolization treatment is effective in patients with unresectable liver cancer

Mean platelet volume in healthy subjects

WOS: 000296573100028

Mean platelet volume in healthy subjects

WOS: 000296573100028

Efficacy of spironolactone therapy in patients with heart failure with normal ejection fraction

balaban, hatice yasemin/0000-0002-0901-9192; balaban, yakup/0000-0001-7553-5075WOS: 000277378600013PubMed: 20448132

Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone

WOS: 000284662700009PubMed: 20859899A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency loom with loss of consciousness due to marked bradycardia caused by hyperkalemia The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor This case is a good example of electrolyte imbalance causing acute life threatening cardiac events Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbanc

Coronary-subclavian steal syndrome presenting with chest pain and syncope

WOS: 000225645600015PubMed: 15636453The present case is a 68-year-old patient with complaints of chest pain and syncopal attacks during physical activity of the left arm, for the last six months. He had a coronary artery bypass graft operation 10 years ago. Angiographic examination demonstrated total occlusion of the subdavian artery. The subdavian artery was stealing blood from the left anterior descending artery via the left internal mammary artery and from the brain via the left vertebral artery, leading to the diagnosis of subdavian artery steal syndrome; a rare cause of coronary and cerebral ischaemia

A case of acute stent thrombosis treated successfully with intracoronary tirofiban

WOS: 000277384900017PubMed: 20425719Acute stent thrombosis (AST) is occasionally observed during percutaneous coronary intervention in patients with acute coronary syndrome (ACS). It may jeopardize hemodynamic status. Currently, there is no adequate solution for this problem. We report our experience with an ACS patient who developed AST associated with cardiogenic shock after percutaneous coronary stent deployment. Intracoronary administration of tirofiban immediately restored the coronary flow of the target vessel, and the disastrous condition was reversed. Our experience suggests that intracoronary administration of tirofiban can be considered as an option in cases of AST during percutaneous coronary intervention

Authors reply

PubMed ID: 23936946[No abstract available